More EVs. Less effort. Lower cost.
The EVlution™ TFF System delivers high-yield, high-purity EV purification from up to 3 litres of starting material - in just 90 minutes. Unlike ultracentrifugation, EVlution™ is affordable, easy to use, and requires minimal hands-on time, freeing you to focus on what matters most: your research.
Its innovative Switch Flow™ technology reduces retentate volume to under 10 mL, maximising recovery while minimising loss. The compact, modular design supports 12 interchangeable polyethersulfone hollow fibre cartridge sizes, including the widely used 300 kDa and 500 kDa options optimised for EV concentration. Filters are reusable up to 20 times, keeping running costs low. EVlution™ pairs seamlessly with Exo-spin™ purification columns for a complete, end-to-end EV workflow.
Whether you're concentrating EVs, depleting FBS-associated particles, or performing buffer exchange, EVlution™ has you covered.
Three single-particle methods dominate the modern EV characterisation toolkit: nanoparticle tracking analysis (NTA), tunable resistive pulse sensing (TRPS) and microfluidic resistive pulse sensing (MRPS). Which should you choose? Or do you need them all?
Several methods have emerged that dominate the field of extracellular vesicle (EV) isolation. Beyond these, many interesting alternatives are on the horizon.
Hydrogels provide physical support and bioactive stimulation. Choosing the right hydrogel for an application is critical, but narrowing down candidates from the huge choice available is a daunting task.
Activin A is the single most important growth factor in iPSC differentiation toward endoderm-derived lineages, and one of the most widely used in cardiac mesoderm protocols as well.
This article examines each of the major parameters governing a TFF-based EV isolation run: membrane format and molecular weight cut-off selection, transmembrane pressure, cross-flow velocity, concentration factor, diafiltration strategy, temperature and hold time. It also covers process monitoring and the role of SEC polishing as a downstream step following TFF.
Not all extracellular vesicles are the same. Learn how exosomes, microvesicles and apoptotic bodies differ in size, biogenesis and cargo, and why the distinction matters for reproducible EV research.
MSC-derived exosomes (and other extracellular vesicles) have become one of the most actively investigated modalities in regenerative medicine, with peer-reviewed evidence spanning cardiac repair, neural regeneration, wound healing, bone and cartilage restoration, and acute organ injury. This article reviews the biological basis of MSC exosome activity, the therapeutic evidence across key disease areas, the manufacturing and isolation considerations that determine product quality, and the tools available to researchers establishing MSC exosome programmes.
Early diagnosis of cancer is critical to treatment outcome. Cancer cells are revealing themselves, secreting vast numbers of extracellular vesicles into the blood. The race is on to identify these hallmarks of cancer with the target of simple mass testing to catch the disease early.
